Portage Biotech, Merck to collaborate on clinical trial

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

The University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has fully implemented the Advarra OnCore Clinical Trials Management System, an investment that strengthens oversight, efficiency, and growth of cancer clinical trials.

January 16, 2026

Vol.52 No.02

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

Cancer Policy

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

Portage Biotech, Merck to collaborate on clinical trial

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

Renew today!

Subscriber content

Never miss an issue!

Login